Compare Medtronic PLC (MDT) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs New York Times Co — how do they compare? Medtronic PLC trades at $82.35 (market cap $106.61B), while New York Times Co trades at $75.18 (market cap $12.29B). The key difference: Medtronic PLC is far larger — about 8.7× New York Times Co's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | NYT | |
|---|---|---|
Market Cap | $106.61B | $12.29B |
Sector | Health | Media |
52-Week High | $105.35 | $85.86 |
52-Week Low | $73.75 | $51.43 |
Enterprise Value | $125.36B | $11.68B |
Dividend Yield | 3.46% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
The New York Times Company (NYSE: NYT) trades at $75.44, down 0.65% today, with a bullish technical signal and strong fundamentals. Revenue grew to $2.82B in 2025, with net income reaching $344M and profit margins expanding to 12.17%. Recent quarters show consistent earnings beats, and the company announced a $0.23 dividend payable July 23, 2026. Positive cash flow from operations of $584M supports financial health, while analyst consensus price target is $78.00.
Outlook remains positive with steady revenue growth and profitability, though high valuation multiples (P/E 32.59) pose risks. Key catalysts include Q2 2026 earnings on August 5, 2026, and ongoing digital subscription growth. Risks involve regulatory pressures from recent subpoenas to journalists and competitive media landscape. Institutional sentiment is mixed with 29% buy ratings, suggesting cautious optimism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
